相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
Jose Fernandez-Velasco et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)
Natalizumab differentially affects plasmablasts and B cells in multiple sclerosis
Alexander Cuculiza Henriksen et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)
Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab
Heinz Wiendl et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies
David Baker et al.
FRONTIERS IN IMMUNOLOGY (2020)
Acquired hemophilia A and other autoimmune diseases after alemtuzumab therapy for multiple sclerosis: A report of two cases
Elizabeth R. Comini-Frota et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis
Wendy Gilmore et al.
JOURNAL OF NEUROINFLAMMATION (2020)
Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab
C. L. Kemmerer et al.
PLOS ONE (2020)
Clinical significance and immunobiology of IL-21 in autoimmunity
Di Long et al.
JOURNAL OF AUTOIMMUNITY (2019)
Anti-thyroid autoantibodies as biomarkers for alemtuzumab associated thyroid autoimmunity
Markus Reindl
EBIOMEDICINE (2019)
Blood lymphocyte subsets identify optimal responders to IFN-beta in MS
Raquel Alenda et al.
JOURNAL OF NEUROLOGY (2018)
Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile
Silvia Medina et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile
Silvia Medina et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis
Antonio Riccardo Buonomo et al.
EXPERT OPINION ON DRUG SAFETY (2018)
Vitiligo after alemtuzumab treatment Secondary autoimmunity is not all about B cells
Tobias Ruck et al.
NEUROLOGY (2018)
An updated histological classification system for multiple sclerosis lesions
Tanja Kuhlmann et al.
ACTA NEUROPATHOLOGICA (2017)
Alemtuzumab CARE-MS II 5-year follow-up
Alasdair J. Coles et al.
NEUROLOGY (2017)
Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
David Baker et al.
JAMA NEUROLOGY (2017)
Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
Tjalf Ziemssen et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2017)
Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination
Ali H. Ellebedy et al.
NATURE IMMUNOLOGY (2016)
Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
Catharina C. Gross et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
Orla Tuohy et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis
Laura Azzopardi et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis
Xin Zhang et al.
JOURNAL OF IMMUNOLOGY (2013)
Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis
Lisa Costelloe et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2012)
Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro
Robert P. Lisak et al.
JOURNAL OF NEUROIMMUNOLOGY (2012)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
Sara A. J. Thompson et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)
Joanne L. Jones et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
分享论文
